RxDoctor Payments Data

Mark Fishel, MD

Neurology · Bellevue, WANPI 1760563407

Payments from drug & device makers

$21,255in general payments, 2019–2025

Across 1,095 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Lilly USA, LLC$1K
  • GE HealthCare$1K
  • Biogen$1K
  • Novartis$916
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$280%
  • Travel & lodging$8854%
  • Food & beverage$19,84693%
  • Education$4952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)113$1,739
Teva Pharmaceuticals USA, Inc.85$1,649
Lilly USA, LLC74$1,403
GE HealthCare12$1,090
Biogen54$1,019
Novartis46$916
Acadia Pharmaceuticals Inc41$819
EMD Serono, Inc.38$777
Eisai Inc.29$721
UCB, Inc.29$663
Upsher-smith Laboratories LLC35$637
Amneal Pharmaceuticals LLC32$569
Neurelis, Inc.23$565
Sunovion Pharmaceuticals Inc.32$563
Amgen33$551
Lundbeck LLC24$501
Supernus Pharmaceuticals, Inc.47$466
Bristol Myers Squibb21$433
Otsuka America Pharmaceutical, Inc.21$365
Collegium Pharmaceutical, Inc.30$344
CSL Behring16$329
Acorda Therapeutics, Inc17$328
Impel Pharmaceuticals Inc.27$314
Assertio Therapeutics, Inc.21$307
Sanofi15$306
Takeda Pharmaceuticals U.S.A., Inc.9$252
SK Life Science, Inc.9$234
Merz Pharmaceuticals, LLC7$218
Avanir Pharmaceuticals, Inc.10$192
Pfizer8$190
Arbor Pharmaceuticals, Inc.8$181
Sumitomo Pharma America, Inc.8$156
Neurocrine Biosciences, Inc.6$123
Alnylam Pharmaceuticals Inc.4$117
Livanova USA, Inc.4$115
AstraZeneca6$113
Ipsen Biopharmaceuticals, Inc6$108
Avion Pharmaceuticals6$107
Catalyst Pharmaceuticals, Inc.4$104
Johnson & Johnson(2 entities)6$103
Amylyx Pharmaceuticals, Inc.5$98
Bausch Health US, LLC5$93
ANI Pharmaceuticals, Inc.3$86
Vanda Pharmaceuticals Inc.3$82
Greenwich Biosciences, Inc.4$81
Alfasigma USA, Inc.4$80
Axsome Therapeutics, Inc.3$75
Ironshore Pharmaceuticals Inc.3$74
Kyowa Kirin, Inc.3$58
Tersera Therapeutics LLC2$55
Biohaven Pharmaceuticals, Inc.3$53
Akcea Therapeutics, Inc.3$52
Tanabe Pharma America, Inc.2$52
Jazz Pharmaceuticals Inc.3$52
Boston Scientific2$48
Azurity Pharmaceuticals, Inc.2$43
Biohaven Pharmaceutical Holding Company Ltd.2$41
Janssen Scientific Affairs, LLC2$39
Grifols USA, LLC3$39
Xeris Pharmaceuticals, Inc.2$37

How this compares

$21,255 in reported general payments places this provider in the 80th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$59,599
Medicare patients
131
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VimpatLacosamide15$23,100
Emgality PenGalcanezumab-Gnlm24$17,067
BriviactBrivaracetam11$16,341
Nurtec OdtRimegepant Sulfate11$14,896
Lamotrigine110$4,002
Depakote SprinkleDivalproex Sodium13$3,879
Levetiracetam98$2,742
Carbamazepine ErCarbamazepine23$2,289
Lacosamide21$2,188
Topiramate46$1,959
Memantine Hcl60$1,950
Carbamazepine43$1,668
Divalproex Sodium36$1,354
Clobazam17$1,270
Amitriptyline Hcl39$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$663$39,44026 claims
PfizerNurtec Odt$190$14,89611 claims
Upsher-smith Laboratories LLCTopiramate$637$1,95946 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$569$32711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 neurology providers in Washington.

Other neurology in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →